Status: Recruiting
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
The goal of this clinical research study is to learn about the safety of giving immune cells called natural killer (NK) cells with chemotherapy to patients with leukemia, lymphoma, or multiple myeloma. Immune system cells (such as NK cells) are made by the body to attack foreign or cancerous cells. Researchers think that NK cells you receive from a donor may react against cancer cells in your body, which may help to control the disease.
Participants needed: 80
Trial details
Phase: Phase 1, Phase 2Age: 12-80Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: Jun 8, 2026Locations: 1
Eligibility criteria
Patients with hematological malignances with an expression of CD70 in the pre-en... [+14]
Positive beta HCG in female of child-bearing potential defined as not postmenopa... [+16]